Intellectual Property
In addition to the orphan drug status granted to Soliris® (eculizumab)
in the United States, European Union, Japan and other territories, Alexion is the
outright owner or licensee of essential patents and related intellectual property
of Soliris and the underlying complement inhibition technology.